Report blinded 12-week interim analysis of the ARGON-2 Phase 2b study of EDP-305
Delivered after the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 8 Feb 2021
- Due
- 30 Jun 2021
- Delivered
- Q3 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Continue recruitment and dosing in ARGON-2 Phase 2b study of EDP-305, with a blinded 12-week interim analysis on a subset of patients, for Enanta’s internal use, expected in mid-year 2021.”
What we found
Evidence strength A What the grades mean
The company delayed the expected mid-year 2021 interim analysis to the third quarter of 2021 due to clinical trial interruptions, subsequently completing it in that period.
-
A Enanta Pharmaceuticals Inc. 10-K filed 2021-11-24
“Based on an internal interim analysis of a subset of patients in a Phase 2 study of EDP-305 at 12 weeks of treatment... we made a business decision in 2021 to prioritize combination approaches” ✓ confirmed on the page
-
A Enanta Pharmaceuticals Inc. 10-Q filed 2021-08-09
“Due to these interruptions, particularly in North America and Europe, we expect to have the internal interim analysis of the ARGON-2 study, together with data from the Phase 1 EDP-297 study, in the third calendar quarter of 2021.” ✓ confirmed on the page
Checked 25 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- blinded 12-week interim analysis
- Target
- 12 weeks
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “Not met”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the recorded outcome.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Enanta Pharmaceuticals Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-ENTA-023290 · Corrections policy